Nuchem Pharmaceuticals Inc.
Records under this name other than patents Nuchem Pharmaceuticals Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Showing 1 to 5 of 5 · Back to Nuchem Pharmaceuticals Inc.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 6,028,103 | Triaryl methane compounds and analogues thereof useful for the treatment or prevention of sickle cell disease or diseases characterized by abnormal cell proliferation Term ended Term ended Mar 19, 2017 · USPTO record | Term ended | Term ended Mar 19, 2017 | USPTO record |
| US 6,992,079 | Substituted 11-Phenyl-DIBENZAZEPINE Compounds Useful for the Treatment or Prevention of Diseases Characterized by Abnormal Cell Proliferation Lapsed on the fee record Ended Jan 31, 2014 · Low confidence | Lapsed on the fee record | Ended Jan 31, 2014 | Low confidence |
| US 6,800,658 | Substituted diphenyl indanone, indane and indole compounds and analogues thereof useful for the treatment of prevention of diseases characterized by abnormal cell proliferation Lapsed on the fee record Ended Oct 5, 2012 · USPTO record | Lapsed on the fee record | Ended Oct 5, 2012 | USPTO record |
| US 7,342,038 | Substituted diphenyl indanone, indane and indole compounds and analogues thereof useful for the treatment or prevention of diseases characterized by abnormal cell proliferation Lapsed on the fee record Ended Mar 11, 2012 · USPTO record | Lapsed on the fee record | Ended Mar 11, 2012 | USPTO record |
| US 6,534,497 | Substitute 11-phenyl-dibenzazepine compounds useful for the treatment or prevention of diseases characterized by abnormal cell proliferation Lapsed on the fee record Ended Mar 18, 2011 · USPTO record | Lapsed on the fee record | Ended Mar 18, 2011 | USPTO record |